In recent history, one of the most crucial medications with significant fashion implications may eventually become significantly easier to utilize. Scientists in France have revealed a cutting-edge hydrogel model of semaglutide, the active compound found in both diabetes treatment Ozempic and weight loss medication Wegovy, as part of a new analysis unveiled Saturday. Researchers propose that a slow-release formulation could enable patients to receive a single monthly dose of these medications, rather than the current weekly requirement.
Scientists at French biotech firm Adocia conducted an analysis as part of their mission to develop innovative formulations of existing medications for diabetes and obesity management. The corporation has successfully developed various forms of insulin that are currently undergoing rigorous scientific testing on a grand scale. This novel gel-based formulation of semaglutide aims to overcome a significant limitation of the original drug – its suboptimal adherence profile.
In clinical trials, individuals using semaglutide achieved an average reduction of approximately 15% in body weight, a level of success occasionally observed when combining diet and exercise. While the treatment has traditionally been considered reliable and manageable, patients may still encounter unpleasant symptoms such as nausea, stomach upset, and other gastrointestinal issues. Despite its effectiveness, only approximately 40% of patients using the medication continue treatment for at least a year. Some drop-offs may be attributed to semaglutide’s dosing regimen, specifically the injectable versions’ once-weekly administration and the daily schedule of the oral tablet formulation, marketed as Rybelsus.
Adocia’s researchers combined two degradable polymers to develop their “Gelzepmic” product, also formally known as AdoGel Sema. The subsequent gel formulation is engineered to initiate a controlled release of the therapeutic agent in an initial surge, followed by a sustained and gradual dispersal over a period of approximately one month. With its one-of-a-kind composition, this gel is designed for straightforward subcutaneous injection.
Researchers observed that in each laboratory experiment and rat study, the gel-based semaglutide performed as expected, gradually releasing its effects over an extended period. Notably, the rats demonstrated no signs of irritation, suggesting safe tolerance without increased toxicity. The group’s research findings were unveiled this weekend at the annual meeting of the European Association for the Study of Diabetes (EASD).
“Glucagon-like peptide-1 agonists (GLP-1) have revolutionized type 2 diabetes management, but the requirement for weekly injections can be a significant burden for patients.” According to lead researcher and Adocia scientist Claire Mégret, a single monthly dose could significantly simplify medication adherence for individuals living with diabetes or weight-related issues, thereby enhancing quality of life and reducing side effects and complications associated with diabetes, as stated at the European Association for the Study of Diabetes (EASD).
Mégret and her team subsequently planned to investigate the gel-like substance in pigs, whose skin and endocrine systems more closely resemble those of humans. If these checks prove profitable, human trials may potentially commence within a few years. The corporation can leverage significant growth opportunities for semaglutide, following preliminary findings indicating that this new formulation is readily absorbed by the body more efficiently than the currently available oral tablet, Rybelsus.
